Catalent
Catalent, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products, is headquartered in the United States. Founded in 2007, Catalent has rapidly expanded its operations across North America, Europe, and Asia, establishing a strong presence in the pharmaceutical and biotechnology industries. The company is renowned for its innovative services, including drug formulation, clinical supply, and commercial manufacturing, which are designed to enhance product performance and patient experience. Catalent's commitment to quality and efficiency has positioned it as a trusted partner for many of the world's top pharmaceutical companies. With a focus on continuous improvement and cutting-edge technology, Catalent remains at the forefront of the industry, achieving significant milestones in drug delivery and development.
DitchCarbon Score
How does Catalent's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Catalent's score of 46 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Catalent's reported carbon emissions
In 2023, Catalent, headquartered in the United States, reported total greenhouse gas emissions of approximately 146,500,000 kg CO2e, comprising 94,512,000 kg CO2e from Scope 1 and 39,600,000 kg CO2e from Scope 2 emissions. This reflects a commitment to transparency in their carbon footprint, with a focus on reducing emissions across their operations. Catalent has set ambitious targets to address its carbon emissions. The company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline year. Additionally, Catalent is committed to a 25% reduction in absolute Scope 3 emissions, which include emissions from fuel- and energy-related activities and employee commuting, also by FY2030. Furthermore, the company plans for 70% of its suppliers, based on emissions, to have science-based targets by FY2028, covering areas such as purchased goods and services, capital goods, and upstream transportation and distribution. In summary, Catalent is actively working towards significant reductions in its carbon emissions, demonstrating a commitment to sustainability and climate responsibility within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 61,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 144,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Catalent is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
